文献速递关节外科

静脉氨甲环酸可安全有效降低翻修全膝关节置换术输血率

Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

该回顾性研究纳入2005至2014年2951例翻修全膝关节置换术,其中1144例(39%)使用静脉氨甲环酸。倾向模型校正后,氨甲环酸组总体输血率13%显著低于非氨甲环酸组39%(p<0.001),无菌性和感染性翻修亚组均显著降低,症状性静脉血栓栓塞事件风险无显著差异(调整p=0.63)。

要点

  • 静脉氨甲环酸使翻修全膝关节置换术总体输血率从39%降至13%(p<0.001)。
  • 无菌性翻修输血率6%对比28%,感染性翻修31%对比54%,均显著降低(p<0.001)。
  • 症状性静脉血栓栓塞事件率约1.2%,校正后两组间无显著差异(调整p=0.63)。

核心结论

  • 静脉氨甲环酸显著降低翻修全膝关节置换术输血率约两倍,无菌性和感染性翻修亚组均获益。
  • 静脉血栓栓塞事件发生率很低(1.2%),倾向模型校正风险后两组间无显著差异。

研究设计与样本

  • 回顾性研究,纳入2005至2014年翻修全膝关节置换术2951例(2219例患者),其中1144例(39%)使用氨甲环酸。
  • 氨甲环酸组平均年龄65岁、女性52%;非氨甲环酸组平均年龄67岁、女性52%。
  • 采用倾向模型校正偏倚,比较两组输血率和症状性静脉血栓栓塞事件,并按无菌性或感染性翻修病因进行分析。

主要发现

  • 总体输血率氨甲环酸组13%对比非氨甲环酸组39%(p<0.001,调整相对风险1.7)。
  • 无菌性翻修输血率氨甲环酸组6%对比非氨甲环酸组28%(p<0.001)。
  • 感染性翻修输血率氨甲环酸组31%对比非氨甲环酸组54%(p<0.001)。
  • 症状性静脉血栓栓塞事件氨甲环酸组11例(1.0%)对比非氨甲环酸组24例(1.3%),调整p=0.63。

关键数值与推荐

  • 静脉氨甲环酸用于翻修全膝关节置换术可显著降低输血率,总体从39%降至13%。
  • 无菌性翻修输血率从28%降至6%,感染性翻修从54%降至31%(均p<0.001)。
  • 症状性静脉血栓栓塞事件调整后无显著差异(调整p=0.63)。

临床怎么用

  • 翻修全膝关节置换术围手术期可考虑静脉使用氨甲环酸以降低输血需求。
  • 无菌性和感染性翻修患者均可从静脉氨甲环酸中获益,且不增加症状性静脉血栓栓塞事件风险。

局限性

  • 回顾性研究设计,证据等级为治疗性III级。
  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of tranexamic acid (TXA) in primary total knee arthroplasty (TKA) have been well established. However, there have been limited data for revision TKAs. The primary aim was to assess the impact of intravenous TXA on transfusion rates and symptomatic venous thromboembolic events (VTEs) in a large revision TKA cohort with or without intravenous TXA utilization. METHODS: A retrospective review of revision TKAs performed from 2005 to 2014 was performed, identifying 2,951 procedures (2,219 patients), in which TXA was utilized in 1,144 procedures (39%). The mean age was 65 years with 52% female patients in the TXA revision group and 67 years with 52% female patients in the non-TXA revision group. Transfusion rates and symptomatic VTEs were the primary outcomes assessed. Comparisons were performed between cohorts, utilizing a unique propensity model to mitigate bias, on the basis of TXA use and subsequently for aseptic or septic revision etiology. RESULTS: Significant reductions in transfusion rates with use of TXA were identified in revision TKAs overall (13% compared with 39%; p < 0.001 [adjusted relative risk, 1.7]), including revisions for both aseptic etiology (6% with TXA compared with 28% without TXA; p < 0.001) and septic etiology (31% with TXA compared with 54% without TXA; p < 0.001). The risk of a postoperative symptomatic VTE was not significantly different (adjusted p = 0.63) with use of TXA at 11 events (1.0%) compared with 24 events (1.3%) in the non-TXA group). CONCLUSIONS: Intravenous TXA significantly reduced transfusion rates in revision TKAs by approximately twofold, including cohorts revised for aseptic and septic etiologies. There was a very low rate of VTEs (1.2%) with no significant difference in the number of VTEs between groups after adjusting risk utilizing propensity modeling. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Hines JT, Petis SM, Amundson AW, et al. Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties. J Bone Joint Surg Am. 2020. PMID: 31977819. doi:10.2106/JBJS.19.00857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。